TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1 Cancer Research Results

TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1, - Tumor Necrosis Factor Receptor Superfamily Member 25 / Death Receptor 3: Click to Expand ⟱
Source:
Type:

TNFRSF25 - Tumor Necrosis Factor Receptor Superfamily Member 25 / Death Receptor 3

Abbreviation: TNFRSF25, DR3

Alternative Names: Death Receptor 3, APO-3, LARD, TRAMP, WSL-1, TR3

Type: Tumor necrosis factor receptor superfamily member / death receptor / immune signaling receptor

Function: DR3 is a type I transmembrane receptor containing an intracellular death domain. Its principal ligand is TL1A/TNFSF15. DR3 signaling can recruit adaptor proteins including TRADD and activate caspase-dependent apoptosis, necroptosis, NF-κB, JNK, and immune-cell activation pathways.

Cancer: ↕ Context-dependent. DR3 activation can induce apoptosis or necroptosis in cancer cells and can enhance antitumor immune responses. However, DR3 can also activate NF-κB-dependent survival or inflammatory signaling, and certain splice variants have been associated with invasion and metastasis in selected cancers.

Favorable Direction in Cancer: Context-dependent. ↑ DR3 death-signaling can be favorable where it promotes apoptosis or necroptosis, whereas ↓ DR3 signaling may be favorable in tumors where DR3 promotes survival, inflammation, invasion, or metastasis.

Interpretation Note: Do not confuse DR3/TNFRSF25 with DcR3/TNFRSF6B. DcR3 is a soluble decoy receptor and is a distinct target.
Scientific Papers found: Click to Expand⟱
8235- LCA,    Anticancer effects of licochalcones: A review of the mechanisms
- Review, Var, NA
mt-Apoptosis↑, TumAuto↑, TumCMig↓, LC3‑Ⅱ/LC3‑Ⅰ↑, ATG5↑, ATG7↑, p62↑, CHOP/DDIT3↑, ER Stress↑, UPR↑, ATG3↑, Beclin-1/ATG6↑, ATG16L1↑, PERK↑, ATF4↑, ATP↓, Hif1a↓, GLUT1↓, PDK1 / PDPK1↓, Bcl-xL↓, Bcl-2↓, BAD↑, BAX↑, Casp3↑, survivin↓, EGFR↓, ERK↓, Akt↓, mtDam↑, MMP↓, Cyt‑c↑, Casp↑, MDM2↓, CycB/CCNB1↓, CDC2↓, CDC25↓, TumCCA↑, TumCP↓, Wnt↓, β-catenin/ZEB1↓, Sp1/3/4↓, MMP-10↓, MMP3↓, TumCI↓, Imm↑, PD-L1↓, ROS↑, 4E-BP1↓, eIF2α↓, PI3K↓, mTOR↓, p‑cMET↑, Ca+2↑, RUBCN↓, ATG13↑, TSC1↑, TSC2↑, PRAS40↑, PP2A↑, ULK1/ATG1↑, THEM4/CTMP↑, DR5↑, Fas↑, TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, PKCδ↓, P70S6K↓, VEGF↓, angioG↓, HK2↓, Glycolysis↓, TrxR1↓, APAF1↑, cl‑PARP↑, Bax:Bcl2↑, ABCG2↓, BioEnh↑,
8244- LCA,    Licochalcone A from licorice root, an inhibitor of human hepatoma cell growth via induction of cell apoptosis and cell cycle arrest
- in-vitro, Liver, HepG2
TumCP↓, ROS↑, TumCCA↑, Apoptosis↑, survivin↓, CycB/CCNB1↓, CDK1↓, WEE1↑, P21↑, cycD1/CCND1↑, JNK↑, TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, DR5↑, Casp3↑, Casp8↑, Casp10↑, Fas↑, BAD↑, BAX↑, PUMA↑, PKCδ↓, P70S6K↓, Akt↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

ATG13↑, 1,   ATG16L1↑, 1,   RUBCN↓, 1,   THEM4/CTMP↑, 1,   TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, 2,   ULK1/ATG1↑, 1,   WEE1↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

ROS↑, 2,   TrxR1↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 1,   CDC2↓, 1,   CDC25↓, 1,   MMP↓, 1,   mtDam↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ATG7↑, 1,   Glycolysis↓, 1,   HK2↓, 1,   PDK1 / PDPK1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 2,   APAF1↑, 1,   Apoptosis↑, 1,   mt-Apoptosis↑, 1,   BAD↑, 2,   BAX↑, 2,   Bax:Bcl2↑, 1,   Bcl-2↓, 1,   Bcl-xL↓, 1,   Casp↑, 1,   Casp10↑, 1,   Casp3↑, 2,   Casp8↑, 1,   Cyt‑c↑, 1,   DR5↑, 2,   Fas↑, 2,   JNK↑, 1,   MDM2↓, 1,   PUMA↑, 1,   survivin↓, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

Sp1/3/4↓, 1,   TSC2↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   eIF2α↓, 1,   ER Stress↑, 1,   PERK↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG3↑, 1,   ATG5↑, 1,   Beclin-1/ATG6↑, 1,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   p62↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   CycB/CCNB1↓, 2,   cycD1/CCND1↑, 1,   P21↑, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

4E-BP1↓, 1,   p‑cMET↑, 1,   ERK↓, 1,   mTOR↓, 1,   P70S6K↓, 2,   PI3K↓, 1,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

Ca+2↑, 1,   MMP-10↓, 1,   MMP3↓, 1,   PKCδ↓, 2,   TSC1↑, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 2,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   ATF4↑, 1,   EGFR↓, 1,   Hif1a↓, 1,   VEGF↓, 1,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Imm↑, 1,   PD-L1↓, 1,  

Protein Aggregation(tgid=19) ⓘ

PP2A↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABCG2↓, 1,   BioEnh↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,   PD-L1↓, 1,  

Functional Outcomes(tgid=23) ⓘ

PRAS40↑, 1,  
Total Targets: 87

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1, - Tumor Necrosis Factor Receptor Superfamily Member 25 / Death Receptor 3
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1789  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page